TABLE 3

Comparison of ¹⁷⁷Lu-DOTATATE and ¹⁷⁷Lu-DOTA-JR11 Organ and Effective Doses of 4 Patients with Neuroendocrine Tumors or Carcinomas

Organ	¹⁷⁷Lu-DOTATATE	¹⁷⁷Lu-DOTA-JR11
Adrenals	0.072 ± 0.019	0.11 ± 0.024
Brain	0.061 ± 0.018	0.10 ± 0.020
Breasts	0.061 ± 0.018	0.10 ± 0.020
Gallbladder wall	0.070 ± 0.020	0.11 ± 0.023
GI (LLI wall)	0.065 ± 0.019	0.11 ± 0.021
GI (small intestine)	0.066 ± 0.019	0.11 ± 0.021
GI (stomach wall)	0.069 ± 0.020	0.11 ± 0.024
GI (ULI wall)	0.066 ± 0.019	0.11 ± 0.021
Heart wall	0.065 ± 0.019	0.11 ± 0.021
Kidneys^*	1.2 ± 0.35	1.8 ± 0.44
Liver	0.25 ± 0.096	0.33 ± 0.16
Lungs	0.065 ± 0.019	0.11 ± 0.021
Muscle	0.063 ± 0.019	0.10 ± 0.020
Ovaries	0.056 ± 0.009	0.10 ± 0.025
Pancreas	0.075 ± 0.021	0.12 ± 0.027
Red marrow	0.079 ± 0.018	0.10 ± 0.021
Osteogenic cells	0.22 ± 0.053	0.35 ± 0.068
Skin	0.060 ± 0.018	0.10 ± 0.019
Spleen	2.5 ± 1.5	3.0 ± 2.3
Thymus	0.063 ± 0.019	0.10 ± 0.020
Thyroid	0.062 ± 0.019	0.10 ± 0.020
Urinary bladder wall	0.26 ± 0.13	0.37 ± 0.21
Uterus	0.066 ± 0.019	0.11 ± 0.021
Total body	0.083 ± 0.021	0.13 ± 0.031
Effective dose (Sv/GBq)	0.15 ± 0.046	0.20 ± 0.075

↵* Only kidney doses were calculated using 3-dimensional voxel-based technique. Range of kidney doses was 0.71–1.45 Gy/GBq for ¹⁷⁷Lu-DOTATATE and 1.44–2.27 Gy/GBq for ¹⁷⁷Lu-DOTA-JR11.
GI = gastrointestinal; LLI = lower large intestine; ULI = upper large intestine.
Data are mean absorbed dose ± SD in Gy/GBq.